Valuation: Compass Therapeutics, Inc.

Market Cap 430M 372M 350M 318M 598M 41.24B 607M 4.1B 1.61B 20.63B 1.62B 1.58B 68.7B P/E 2026 *
-4.79x
P/E 2027 * -4.39x
Enterprise Value 280M 242M 228M 207M 390M 26.87B 395M 2.67B 1.05B 13.44B 1.05B 1.03B 44.76B EV / Sales 2026 *
-
EV / Sales 2027 * 13.3x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+1.88%
1 week+3.38%
Current month+28.27%
1 month+21.29%
3 months+35.36%
6 months-61.66%
Current year-54.38%
1 week 2.2
Extreme 2.2
2.5
1 month 1.85
Extreme 1.85
2.5
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 27/05/2024
Director of Finance/CFO 54 08/12/2024
Chief Tech/Sci/R&D Officer 50 31/12/2025
Director TitleAgeSince
Director/Board Member 65 31/12/2013
Director/Board Member 64 31/12/2014
Chairman 61 31/12/2014
Date Insider Type Main position Quantity % Market Cap.
08/02/26 Tax

Chief Executive Officer

36,687 0.0206%
09/01/26 Tax

Chief Executive Officer

46,777 0.0263%
02/01/26 Free

Director

90,000 0.0506%
Change 5-day change 1-year change 3-year change Capi.($)
+1.88%+3.38%-9.93%+3.81% 430M
+0.17%+4.35%+72.39%+114.97% 73.45B
+1.03%+15.45%+57.17%+92.63% 62.99B
+0.05%-2.77%+1.10%+484.59% 28.05B
-1.40%+4.18%+54.52%+19.60% 25.42B
+22.11%+22.75%+2.19%-3.14% 23.3B
+2.23%+5.50%+41.80%-13.87% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+17.17%+534.55% 16.53B
+2.13%+7.87%+44.84%+154.31% 13.16B
Average +2.35%+3.77%+52.52%+181.13% 28.1B
Weighted average by Cap. +1.94%+5.48%+58.73%+165.85%

Financials

2026 *2027 *
Net sales - 22.39M 19.34M 18.2M 16.54M 31.11M 2.15B 31.56M 213M 83.65M 1.07B 84.08M 82.25M 3.57B
Net income -93.8M -81.02M -76.22M -69.28M -130M -8.99B -132M -894M -350M -4.49B -352M -345M -14.97B -108M -93.17M -87.66M -79.67M -150M -10.34B -152M -1.03B -403M -5.17B -405M -396M -17.22B
Net Debt -150M -130M -122M -111M -208M -14.37B -211M -1.43B -560M -7.19B -563M -551M -23.94B -133M -115M -108M -98.23M -185M -12.74B -187M -1.27B -497M -6.37B -499M -489M -21.23B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
19/08/26 US$2.435 +1.88% 653,491
18/08/26 US$2.390 +3.46% 2,934,326
17/08/26 US$2.310 +2.67% 2,369,229
14/08/26 US$2.250 -0.44% 1,362,180
13/08/26 US$2.260 -4.64% 2,272,293
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.390USD
Average target price
8.917USD
Spread / Average Target
+273.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock